P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

August 2010

Features

Expenditures Associated with Dose Titration at Initiation of Therapy in Patients with Major Depressive Disorder

A Retrospective Analysis of a Large Managed Care Claims Database

Although selective serotonin reuptake inhibitors (SSRIs) are considered cost-effective for major depression, dosage adjustments may be necessary when therapy starts. In the authors' study, patients undergoing dose titration of SSRIs used more medical resources and spent more days receiving a subtherapeutic dose than comparable controls not undergoing dose titration.
Fabian Camacho, MS, MA; Meg C. Kong, PhD; David V. Sheehan, MD, MBA; and Rajesh Balkrishnan, PhD

Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States

Part 1: The Widespread Use of CAM and the Need for Better-Informed Health Care Professionals to Provide Patient Counseling

Pharmacists and physicians are in an ideal position to counsel patients on the use of dietary supplements and CAM, but many currently lack the formal training needed to help the growing number of people who wish to use these treatments. Standards have been issued to guide health care professionals, but more initiatives are needed.
C. Lee Ventola, MS

Meeting Highlights

American Society of Clinical Oncology, 2010 Annual Meeting and Rose Bengal: From a Wool Dye to a Cancer Therapy

Topics include medications for chronic myelogenous leukemia, melanoma, multiple myeloma, breast cancer, renal cell carcinoma, and lung cancer. The centuries-old history of rose bengal, a promising agent for melanoma, is also presented.
Walter Alexander

Pharmaceutical Approval Update

Cabazitaxel (Jevtana) injection for hormone-refractory prostate cancer, aztreonam inhalation solution (Cayston) for improving respiratory symptoms in cystic fibrosis, and denosumab (Prolia) for postmenopausal women with osteoporosis are discussed.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

How Healthy Is Your County?

A new report ranks the health of each county in the U.S., with an emphasis on quality-of-care measures designed to improve the overall health of residents.
David B. Nash, MD, MBA

Medication Errors

Reducing Errors with Injectable Medications

Unlabeled Syringes Are Surprisingly Common

Reducing errors involving injectable drugs can be accomplished if syringes are labeled appropriately.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

New Mandate for Covering Mental Health And Substance Abuse May Force Employers To Reduce Hospital and Drug Benefits

A new law requiring insurance coverage for mental health and substance abuse might force companies to reduce hospital and drug benefits for their employees.
Stephen Barlas

Drug News

FDA approvals, drug indications, product recalls, and industry updates

Drug Forecast

Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha2A-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder

Guanfacine extended-release (Intuniv) tablets, a nonstimulant agent for attention/deficit hyperactivity disorder in children and adolescents
Martin P. Cruz, PharmD, CGP, BCPP